Evidence map›Paper›PMID 42855467›Full record

ArticleExperimental & molecular medicine2026

PET imaging enables direct evaluation of ferroptosis in HCC synergistically induced by anti-PD-L1 and Olaparib.

Feng Xiong, Cheng Xu, Pei Wang, Ni Li, Yilin Yang, Buchuan Zhang, Kijung Kwak, Shuang Song, Pengtao You, Xiaohua Zhu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Feng Xiong *Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cheng Xu *Hubei University of Chinese Medicine, Wuhan, Hubei Province, China.
Pei Wang *Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ni Li *Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yilin YangDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Buchuan ZhangDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kijung KwakUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Shuang SongDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pengtao YouHubei University of Chinese Medicine, Wuhan, Hubei Province, China. tptyou@hbucm.edu.cn.
Xiaohua ZhuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dalong NiDepartment of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ndl12353@rjh.com.cn.ORCID http://orcid.org/0000-0001-6679-5414
Bo YuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. yuboxf@hotmail.com.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22407084National Natural Science Foundation of China (National Science Foundation of China) 81601605National Natural Science Foundation of China (National Science Foundation of China) 81873903
6 · The paper itself

Abstract

The efficacy of PET image-guided immune checkpoint inhibitor-based therapy in hepatocellular carcinoma (HCC) management is limited by the lack of direct monitoring of therapeutic response. A key challenge is the mismatch between the therapeutic pathway and the imaging target, which hinders the accurate assessment of treatment outcomes. We addressed this challenge by combining anti-PD-L1 immunotherapy with Olaparib, a strategy that promotes ferroptosis in BRCA wild-type HCC by suppressing SLC7A11, thus allowing for therapeutic response evaluation via [

Identifiers

PMID42855467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.